First Malaria Vaccine RTS, S: A Step toward the Eradication of Malaria

Area of Science:

• Global Health
• Infectious Diseases
• Parasitology

Background:

• Malaria, a Plasmodium parasite infection, endangers 50% of the global population.
• Artemisinin (ART)-based combination therapies are WHO-endorsed treatments for uncomplicated malaria.
• Malaria cases rose to 247 million in 2021, partly due to COVID-19 pandemic disruptions.

Purpose of the Study:

• To highlight the current malaria situation and the impact of global health initiatives.
• To discuss advancements in malaria prevention and treatment, including vaccines.
• To underscore the ongoing research and development in malaria eradication strategies.

Main Methods:

• Review of global malaria statistics and World Malaria Report (2022).
• Analysis of World Health Organization (WHO) recommendations and vaccine prequalification.
• Overview of ongoing clinical development for novel malaria vaccines.

Main Results:

• The RTS,S vaccine, the first malaria vaccine, received WHO prequalification in July 2022.
• Over one million children in African nations have received at least one RTS,S vaccine dose.
• Research is progressing on next-generation malaria vaccines, including mRNA technologies.

Conclusions:

• The RTS,S vaccine marks a significant milestone in malaria control efforts.
• Continued development of advanced malaria vaccines is crucial for future eradication programs.
• Global collaboration is essential to address the persistent threat of malaria.